Femtobiomed is a cell engineering device manufacturing company that has been working on research and development for the past ten years. They aim to deliver non-viral genetic materials to target cells. In early 2022, they launched their first commercial product, the CellShot device and platform. This technology allows for one-day, on-site treatment through the delivery of non-viral genetic materials.
The CellShot device and platform uses a patented ‘Real Flow Transfection’ technology. Using a multiple port cartridge, the customized mRNA is delivered to target cells. The company aims to expand the target cells to broaden the target diseases. They will ‘Scale-Out’ the transfection technology to deliver new medicine to patients quicker.
Location: South Korea
Member count: 11-50
Investors 2
| Date | Name | Website |
| - | Korea Inve... | partners.k... |
| - | ABC Partne... | abc-partne... |